XERS
Price
$4.58
Change
+$0.12 (+2.69%)
Updated
Jun 6 closing price
Capitalization
714.29M
59 days until earnings call
YMAB
Price
$5.27
Change
+$0.17 (+3.33%)
Updated
Jun 6 closing price
Capitalization
231.46M
60 days until earnings call
Interact to see
Advertisement

XERS vs YMAB

Header iconXERS vs YMAB Comparison
Open Charts XERS vs YMABBanner chart's image
Xeris Biopharma Holdings
Price$4.58
Change+$0.12 (+2.69%)
Volume$1.82M
Capitalization714.29M
Y-mAbs Therapeutics
Price$5.27
Change+$0.17 (+3.33%)
Volume$110.17K
Capitalization231.46M
XERS vs YMAB Comparison Chart
Loading...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
XERS vs. YMAB commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is XERS is a StrongBuy and YMAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (XERS: $4.78 vs. YMAB: $4.62)
Brand notoriety: XERS and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: XERS: 50% vs. YMAB: 102%
Market capitalization -- XERS: $714.29M vs. YMAB: $231.46M
XERS [@Biotechnology] is valued at $714.29M. YMAB’s [@Biotechnology] market capitalization is $231.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

XERS’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • XERS’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, YMAB is a better buy in the long-term than XERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

XERS’s TA Score shows that 4 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • XERS’s TA Score: 4 bullish, 5 bearish.
  • YMAB’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than XERS.

Price Growth

XERS (@Biotechnology) experienced а -2.85% price change this week, while YMAB (@Biotechnology) price change was +12.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

XERS is expected to report earnings on Aug 06, 2025.

YMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XERS($714M) has a higher market cap than YMAB($231M). XERS YTD gains are higher at: 41.003 vs. YMAB (-40.996). XERS has higher annual earnings (EBITDA): -13.99M vs. YMAB (-30.67M). XERS has more cash in the bank: 71.6M vs. YMAB (67.2M). YMAB has less debt than XERS: YMAB (820K) vs XERS (271M). XERS has higher revenues than YMAB: XERS (203M) vs YMAB (87.7M).
XERSYMABXERS / YMAB
Capitalization714M231M309%
EBITDA-13.99M-30.67M46%
Gain YTD41.003-40.996-100%
P/E RatioN/AN/A-
Revenue203M87.7M231%
Total Cash71.6M67.2M107%
Total Debt271M820K33,049%
FUNDAMENTALS RATINGS
XERS vs YMAB: Fundamental Ratings
XERS
YMAB
OUTLOOK RATING
1..100
7216
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
71100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for XERS (91). This means that YMAB’s stock grew somewhat faster than XERS’s over the last 12 months.

XERS's Profit vs Risk Rating (71) in the Pharmaceuticals Major industry is in the same range as YMAB (100). This means that XERS’s stock grew similarly to YMAB’s over the last 12 months.

YMAB's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as XERS (100). This means that YMAB’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as YMAB (65). This means that XERS’s stock grew similarly to YMAB’s over the last 12 months.

XERS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as YMAB (100). This means that XERS’s stock grew similarly to YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
XERSYMAB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 12 days ago
80%
Bullish Trend 12 days ago
90%
Momentum
ODDS (%)
Bearish Trend 12 days ago
80%
Bullish Trend 12 days ago
90%
MACD
ODDS (%)
Bearish Trend 12 days ago
80%
Bullish Trend 12 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
79%
Bullish Trend 12 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
87%
Bullish Trend 12 days ago
82%
Advances
ODDS (%)
Bullish Trend 24 days ago
85%
Bullish Trend 12 days ago
81%
Declines
ODDS (%)
Bearish Trend 18 days ago
82%
Bearish Trend about 1 month ago
88%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
84%
Bearish Trend 12 days ago
90%
Aroon
ODDS (%)
Bullish Trend 12 days ago
85%
Bearish Trend 12 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-1.04%
TRDA - XERS
51%
Loosely correlated
+0.91%
XNCR - XERS
48%
Loosely correlated
-2.58%
KRYS - XERS
46%
Loosely correlated
-2.44%
CGON - XERS
45%
Loosely correlated
-0.94%
YMAB - XERS
45%
Loosely correlated
+4.76%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ARWR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
+4.76%
ARWR - YMAB
51%
Loosely correlated
+1.24%
CRSP - YMAB
49%
Loosely correlated
-0.92%
NTLA - YMAB
48%
Loosely correlated
+3.59%
FATE - YMAB
47%
Loosely correlated
+4.10%
IMNM - YMAB
47%
Loosely correlated
+0.35%
More